Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TLPHBullishCorporate Developmentsnews

High materiality8/10

Talphera Nafamostat CRRT trial progress signals potential US market upside

Aug 12, 2026, 4:13 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Clinical trial progress and favorable KDIGO citations can unlock regulatory and commercial upside; Nasdaq compliance reduces delisting risk; potential TAM expansion from 200k US CRRT procedures supports multiple expansion.

AI summary

What happened, with direct paths to the underlying reporting

Talphera reports 75% enrollment in its NEPHRO CRRT nafamostat trial with completion expected by year-end 2026, while KDIGO's 2026 guideline references nafamostat as an acceptable regional anticoagulant. Updated US market research indicates approximately 200,000 CRRT procedures in 2027, a 21% rise, supporting a larger TAM if approved. The company sits on $17.1 million cash and is hosting an investor event as enrollment nears completion, reinforcing potential upside on favorable regulatory and commercial dynamics.

75% NEPHRO CRRT nafamostat enrollment; completion expected by year-end.
KDIGO 2026 guidelines cite nafamostat as acceptable CRRT anticoagulant.
US CRRT procedures estimated ~200,000 annually in 2027, up 21%.
Cash and investments $17.1 million as of 6/30/2026; investor event planned.
Regained Nasdaq compliance with the $1 bid price rule.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.